Background: Insulin-like growth factor I (IGF-I) is a key regulator of chondrogenesis, but its therapeutic application to articular cartilage damage is limited by rapid elimination from the repair site. The human IGF-I gene gives rise to three IGF-I propeptides (proIGF-IA, proIGF-IB and proIGF-IC) that are cleaved to create mature IGF-I. In this study, we elucidate the processing of IGF-I precursors by articular chondrocytes, and test the hypotheses that proIGF-I isoforms bind to heparin and regulate articular chondrocyte biosynthesis.
Introduction
Insulin-like growth factor I (IGF-I) plays a central role in skeletal growth and development. Global IGF-I knockout in mice produces marked embryonic and postnatal growth failure [1] . The liver is the main source of circulating IGF-I and liver-specific IGF-I gene knockout mice have a greater than 75% reduction of circulating IGF-I levels. Despite the low levels of circulating IGF-I, these mice develop and grow normally through the autocrine/paracrine action of locally produced IGF-I [2, 3] . IGF-I is produced by chondrocytes [4] and is an important growth factor for cartilage development and homeostasis [5] .
IGF-I also has the potential to serve as a therapeutic agent for articular cartilage repair. Delivery of
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A N U S C R I P T 3 exogenous IGF-I, or production of endogenous IGF-I by gene transfer, stimulates chondrocyte proliferation and the synthesis and production of glycosaminoglycan and collagen, the two major components of cartilage matrix [6, 7] . In addition, IGF-I inhibits the endogenous catabolic breakdown of articular cartilage matrix and the catabolic actions of inflamatory cytokines that are thought to mediate cartilage damage in arthritis [8, 9] . IGF-I promotes articular cartilage repair in both in vitro and in vivo cartilage repair models [10] [11] [12] . These features make IGF-I an attractive candidate for treating damaged articular cartilage in joint disease.
The human IGF1 gene has six exons. Alternative splicing at the 5' and 3' ends of the gene gives rise to two classes and three groups of IGF-I mRNA transcript variants (1A, 1B and 1C, and 2A, 2B and 2C).
Classes 1 and 2 variants arise from exon 1 and exon 2, respectively. Group A variants exclude exon 5 while group B variants exclude exon 6. Group C variants are produced by an internal splice site within exon 5, which causes a frame shift and premature termination in exon 6 ( Figure 1 ). After translation, the six IGF-I mRNA variants give rise to six corresponding IGF-I prepropeptides, each consisting of an Nterminal signal peptide, mature peptide and a C-terminal E peptide. The removal of signal peptides from the six IGF-I prepropeptides results in three IGF-I propeptides (proIGF-IA, proIGF-IB and proIGF-IC), each containing a different E peptide (EA peptide, EB peptide or EC peptide). The EA peptide (35 amino acids), EB peptide (77 amino acids) and EC peptide (40 amino acids) share the first 16 amino acid sequence from Exon 4. Cleavage of the E peptides from the three IGF-I propeptides results in the same mature IGF-I peptide ( Figure 1 ). Secreted proIGF-I has been detected in vitro in medium from cultured cell lines [13, 14] , and in vivo in serum [15] . IGF-I precursor processing by articular chondrocytes and the potential role of proIGF-I peptides in articular chondrocyte function remain unknown.
In articular cartilage, the bioavailability of growth factors is determined, in part, by their interaction with matrix molecules that retain them in the vicinity of articular chondrocytes. Prominent among these matrix molecules is the family of polyanionic sulfated glycosaminoglycans. Heparin and the closely related A C C E P T E D M A N U S C R I P T 4 molecule, heparan sulfate (HS), are the most negatively charged members of this family [16] . Heparin and HS bind to multiple protein ligands, termed heparin-binding proteins (HBPs). HBPs are a diverse group of molecules that include growth factors as well as extracellular matrix components, enzymes, and the cell surface proteins of pathogens [17, 18] . Mutational analysis of heparin-binding segments in these
HBPs by site-directed mutagenesis has revealed specific surface motifs enriched in clusters of basic amino acids, especially arginines and lysines. Some of the common putative heparin-binding segments are XBBXBX, XBBBXXBX, and XBBXXBBBXXBBX, where B is one of the three basic amino acids (mainly arginine and lysine) and X is any of the other 17 natural amino acids. These heparin binding segments function by electrostatic interaction with the negatively charged sulfate and carboxyl groups in heparin or heparan sulfate [19] .
Several growth factors, including some bone morphogenetic proteins (BMPs), fibroblast growth factors (FGFs), and transforming growth factor betas (TGF-βs), have been identified as heparin-binding proteins [20] . Cell surface heparan sulfate proteoglycans often modulate the binding of these growth factors to their receptors and regulate their biologic activities [17] . Mature IGF-I lacks a heparin binding motif and does not bind to heparin or heparin sulfate [21] .
For many glycoproteins, glycosylation is a critical step in producing a fully functional protein [22] .
Human proIGF-IA contains one putative N-glycosylation site at Asn92, located in the EA peptide in the 19 amino acid region from Exon 6 ( Figure 1D ). Glycosylated human proIGF-IA and its glycosylated cleaved EA peptide have been detected in culture medium from IGF-I-overexpressing HEK293 cells and IM9 B-lymphocytes [14, 23] . There is no putative N-glycosylation site in human proIGF-IB or proIGF-IC. It is not known if glycosylation plays a role in the processing or function of proIGF-I isoforms.
The goals of this study were to 1) elucidate the processing of IGF-I precursors by articular chondrocytes, 2) determine whether proIGF-I isoforms bind to heparin and 3) test the hypothesis that proIGF-I isoforms regulate articular chondrocyte biosynthesis.
Materials and methods

Expression vector construction
The cDNAs encoding each of the 6 human IGF-I prepropeptides: 1A (Genebank accession number NM_000618), 1B (Genebank accession number NM_001111285), 1C (Genebank accession number NM_001111283), 2A (Genebank accession number NM_001111284), 2B and 2C, were generated by reverse transcription and PCR using a total RNA preparation of human articular chondrocytes. The human articular chondrocytes were isolated from de-identified articular cartilage discarded at the time of total knee arthroplasty. Because the tissue was de-identified medical waste, this protocol was determined to be exempt by the Indiana University Institutional Review Board. Forward primer IGF-I-F1 with reverse primer IGF-I-R(A), IGF-I-R(B) or IGF-I-R(C) ( Table 1) were used to amplify IGF-I1A, 1B and 1C cDNAs, respectively. Similarly, forward primer IGF-I-F2 (Table 1) with the reverse primer IGF-I-R(A), IGF-I-R(B) or IGF-I-R(C) were used to amplify IGF-I2A, 2B and 2C cDNAs, respectively. The PCR products were cloned into pCR2.1-TOPO TA vector (Life Technologies) respectively, and the sequences were confirmed. Based on prior work with IGF-I and transfection of articular chondrocytes [24] , the adeno-associated virus-based plasmid vector, pAAV-MCS, was selected for cDNA delivery and the cytomegalovirus (CMV) was used as the promoter. Each of the IGF-I cDNAs was subcloned into pAAV-MCS (Stratagene) to obtain pAAV-IGF-I1A, 1B, 1C, 2A, 2B and 2C.
The cDNA encoding human IGF-I prepropeptide 1A without E peptide (IGF-I1A-noEA) was generated by PCR using pAAV-IGF-I1A as a template and forward primer IGF-I-F1 with reverse primer IGF-I- Table 1 ). The cDNA encoding human IGF-I prepropeptide 1A without the C-terminal 19 amino acid sequence of the Exon 6 in human IGF-I gene (IGF-I1A-noEx6) was generated by PCR using pAAV-IGF-I1A as a template and forward primer IGF-I-F1 with reverse primer IGF-I-R(noEx6) ( Table   1 ). The cDNA encoding human IGF-I prepropeptide 1A, including a flag tag at C-terminus (IGF-I1A-flag), was generated by PCR using pAAV-IGF-I1A as a template and forward primer IGF-I-F1 with reverse primer IGF-I-R(flag) ( Table 1 ). The PCR products were cloned into pCR2.1-TOPO TA vector (Life Technologies), respectively. After confirming the sequences, the cDNAs were subcloned into pAAV-MCS (Stratagene) to obtain pAAV-IGF-I1A-noEA, pAAV-IGF-I1A-noEx6 and pAAV-IGF-I1A-flag, respectively.
The cDNA encoding a mutant of human IGF-I prepropeptide 1A, in which the putative N-glycosylation site Asn92 in EA peptide was replaced by Ala (IGF-I1A-N92A), was generated by PCR-based mutagenesis using forward primer IGF-I-F-N92A with reverse primer IGF-I-R-N92A (Table 1) . In order to perform PCR-based mutagenesis, IGF-I1A cDNA in pAAV-IGF-I1A was sub-cloned into pCMV-MCS (Stratagene) and the resulting plasmid pCMV-IGF-I1A was used as as a template. The cDNA encoding a mutant of human IGF-I prepropeptide 1A, in which the three Arg (Arg71, Arg74 and Arg77) in the EA peptide were replaced by Ala (IGF-I1A-R/A), was generated by PCR-based mutagenesis using pCMV-IGF-I1A as a template and forward primer IGF-I-F-R/A with reverse primer IGF-I-R-R/A ( Table   1 ). The cDNA encoding a mutant of human IGF-I prepropeptide 1A, in which the three Arg (Arg71, Arg74 and Arg77) in the EA peptide were replaced by Lys (IGF-I1A-R/K), was generated by PCR-based mutagenesis using pCMV-IGF-I1A as a template and forward primer IGF-I-F-R/K with reverse primer IGF-I-R-R/K ( Table 1 ). The mutation in each of the resulting expression vectors pCMV-IGF-I1A-N92A, pCMV-IGF-I1A-R/A and pCMV-IGF-I1A-R/K, was confirmed by sequencing.
Chondrocyte cell culture and transfection
Dulbecco's minimum essential medium (DMEM), fetal bovine serum (FBS), penicillin, streptomycin, glutamine and proteinase k were from Life Technologies. Ascorbic acid was from Sigma. Basal medium was prepared with DMEM, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine and 50 μg/ml ascorbic acid. Complete medium was prepared with basal medium supplemented with 10% FBS. Bovine articular chondrocytes were isolated as previously described [24] . Briefly, chondrocytes were isolated from the carpal articular cartilage of skeletally mature (physes closed) bovids and placed in monolayer culture in 6 -well plates at a density of 3x10 5 cells/well in 4 ml of complete medium. After 3 days, cells were transfected using FuGENE 6 (Roche Applied Science) and 2 μg of each plasmid DNA per well. The ratio of plasmid DNA (μg) to FuGENE 6 reagent (μl) was 1:3. Transfection with empty vector pAAV-MCS was used as a control. After 16 hours, transfection was stopped by replacing the medium with 4 ml of fresh complete medium. On day 2 and day 4 after transfection, conditioned medium (CM) was collected and replaced by basal medium. On day 6, CM was collected and the cell layer was digested in 2 ml proteinase k solution (0.5 mg/ml proteinase k in 10 mM Tris, pH 8.2, and 5 mM EDTA) at 65ºC for 2 h. CM was stored at -20°C for analyses of IGF-I and proteoglycan in medium. The cell digest was stored at -20°C for analyses of proteoglycan and DNA in the cell layer.
IGF-I analysis
IGF-I in conditioned medium was measured by human IGF-I ELISA (R&D Systems, Cat.#: D291)
according to the manufacturer's procedures. Specifically, the capture antibody of the sandwich ELISA was mouse anti-human IGF-I monoclonal antibody raised using human mature IGF-I as antigen. The detection antibody was goat anti-human IGF-I polyclonal antibody raised using human mature IGF-I as antigen.
Phosphate buffered saline (PBS, 11.9 mM phosphate, 137 mM sodium chloride, 2.7 mM potassium Chemiluminescent substrate (Thermo Scientific, Cat.#: 34080) was used for detection of horseradish peroxidase on immunoblots. CL-X posure films (Thermo Scientific) were exposed to immunoblots and developed using Kodak Medical X-ray processor 104.
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Proteoglycan and DNA analysis
Glycosaminoglycan (GAG) released into the medium (released GAG) and retained with the chondrocytes (cell-associated GAG) were separately measured by dimethylmethylene blue (DMB) assay of conditioned medium or proteinase k cell digest, as previously described [7] . Chondroitin sulfate A (Sigma) was used as the standard. DMB solution was prepared as follows: 1,9-dimethylmethylene blue (32 mg) was dissolved in 5 ml ethanol; 4 g sodium formate and 4 ml formic acid were added, and the volume was made up to 1 liter with water. DMB solution was stored in a brown glass bottle at room
temperature. Each sample or sample diluted with water, was mixed with DMB solution (1:1 volume) and the absorbance at 535 nm was read using DU640 Spectrophotometer (Beckman Coulter) or ELX808 Ultra
Microplate Reader (BioTek Instruments). Cell proliferation was assessed by DNA analysis of the cell digest as previously described [7] by Picogreen dsDNA assay (Molecular Probes) according to the manufacturer's instructions using pure phage λ DNA as the standard.
Statistical Analysis
Three independent experiments were performed using three different batches of bovine articular chondrocytes isolated from three different animals at different times. Data are presented as means ± SD of three independent experiments. The overall group effect was evaluated using ANOVA, followed by pair-wise comparisons between groups using Fisher's Protected Least Significant Differences. A logarithmic transformation of the data was used for the analyses. A 5% significance level was used for all tests.
Results
Transfected articular chondrocytes synthesize and process IGF-I precursors from their respective transgenes.
To determine how chondrocytes process IGF-I precursors, we transfected primary bovine chondrocytes with each of pAAV-IGF-I1A, 1B, 1C, 2A, 2B and 2C, and measured IGF-I in the CM by ELISA. IGF-I1A and IGF-I2A CM contained the highest IGF-I levels (127.0 ng/ml and 143.7 ng/ml respectively), followed by IGF-I1C and IGF-I2C CM (99.6 ng/ml and 118.6 ng/ml respectively) and IGF-I1B and IGF-I2B CM (31.0 ng/ml and 54.9 ng/ml, respectively) ( Figure 2A) .
To characterize IGF-I isoforms produced from the different cDNAs, we analyzed the chondrocyte CM by western blot using anti-IGF-I antibody. The western blots showed three bands in IGF-I1A and IGF-I2A CM, two bands in IGF-I1B and IGF-I 2B CM, and two bands in IGF-I1C and IGF-I2C CM ( Figure 2C ).
The relative molecular mass (Mr) of the bands was the same for classes 1 and 2 of the 3 IGF-I isoforms (1A vs 2A, 1B vs 2B and 1C vs 2C). The lowest Mr band in all western blots was similar to the Mr of recombinant human IGF-I, and was interpreted as mature human IGF-I. Thus, the western blot data suggest that, in addition to mature human IGF-I, the transfected chondrocytes secreted two proIGF-IA forms in IGF-I1A and IGF-I2A CM, one proIGF-IB form in IGF-I1B and IGF-I2B CM and one proIGF-IC form in IGF-I1C and IGF-I2C CM, respectively.
Human IGF-I propeptide A binds to heparin
To determine whether the IGF-I produced by transfected chondrocytes binds to heparin, 
The 19 amino acid sequence from Exon 6 in EA peptide mediates proIGF-IA binding to heparin
To examine the effect of the two parts of the EA peptide ( Figure 1D ) on heparin binding activity by proIGF-IA, we measured IGF-I ( Figure 3A ) and heparin binding activity ( Figure 3B 
N-glycosylation in EA peptide plays an important role in mediating proIGF-IA binding to heparin
To determine whether the EA peptide is glycosylated and, if so, whether glycosylation is involved in proIGF-IA binding to heparin, we transfected chondrocytes with a vector carrying IGF-I1A mutated to
Ala at Asn92 (pCMV-IGF-I1A-N92A), the putative N-glycosylation site in EA peptide ( Figure 1D ).
Vectors pAAV-IGF-I1A and pAAV-IGF-I1A-noEA were used for comparison. The IGF-I ELISA results
showed that the change of Asn92 to Ala abrogated heparin binding activity without affecting IGF-I expression ( Figure 5A and Figure 5B ). Western blot showed only two bands in IGF-I1A-N92A CM, corresponding to the two lower Mr bands of the three bands present in IGF-I1A CM. The highest Mr band in IGF-I1A CM disappeared in IGF-I1A-N92A CM ( Figure 5C ). These results further suggest that the highest Mr band in IGF-I1A CM is glycosylated proIGF-IA, and that the heparin binding activity of proIGF-IA is dependent on this glycosylation.
Comparison of proIGF-IA, BMP-2 and TGF-β1 binding to heparin
We evaluated the interactions of proIGF-IA, BMP-2 and TGF-β1 with heparin by FPLC analysis.
The results indicate that BMP-2, TGF-β1 and proIGF-IA, each specifically bind to heparin and that the heparin binding affinity of proIGF-IA is higher than that of TGF-β1, but lower than that of BMP-2 ( Figure 6 ). 
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ProIGF-IA mutated at Arg71, Arg74 and Arg77 is resistant to EA peptide cleavage
Chondrocytes were transfected with vectors carrying IGF-I1A mutated at Arg71, Arg74 and Arg77
( Figure 1D ), three amino acids that are involved in EA peptide cleavage [23] , to either Ala (pCMV-IGF-I1A-R/A) or Lys (pCMV-IGF-I1A-R/K). The latter was selected to retain basic amino acids at these sites.
pAAV-IGF-I1A and pAAV-IGF-I1A-noEA were used for comparison. IGF-I production was measured by IGF-I ELISA of CM ( Figure 7A ) and examined by western blot using IGF-I antibody ( Figure 7B ). The western blots showed one major, high Mr band, consistent with N-glycosylated proIGF-IA, and one minor, medium Mr band consistent with unglycosylated proIGF-IA in CM from both IGF-I1A-R/A and IGF-I1A-R/K transfected chondrocytes. No band representing mature peptide was detected ( Figure 7B ).
These data are consistent with the absence of proIGF-I cleavage by the chondrocytes. Interestingly, the data also showed that the change of Arg71, Arg74 and Arg77 to Ala increased IGF-I production by the cells, whereas the change of Arg71, Arg74 and Arg77 to Lys decreased IGF-I production, compared to production from IGF-I1A.
ProIGF-IA stimulates biosynthetic activity by articular chondrocytes
To determine whether the IGF-I propeptides possess biological activity, chondrocytes were transfected with the above vectors and the cell layer was assayed for DNA content as an index of cell proliferation. The cell layer and conditioned medium were assayed for glycosaminoglycan (GAG) content as an index of cartilage matrix production. Chondrocytes transfected with pCMV-IGF-I1A-R/A, pCMV-IGF-I1A-R/K, pAAV-IGF-I1A, or pAAV-IGF-I1A-noEA increased DNA content over a range of 1.7-2.0 times controls (p < 0.001) ( Figure 7C ). The transfected cells produced 1.8-2.3 times more released GAG (p < 0.005) and 2.0-2.7 times more cell-associated GAG (p < 0.001) than controls ( Figure 7D ). Empty vector pAAV-MCS was used as control.
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15 Western blot data demonstrate that chondrocytes transfected by pAAV-IGF-I1A produced both proIGF-IA and mature IGF-I. In contrast, chondrocytes transfected by pAAV-IGF-I1A-noEA produced only mature IGF-I, and those transfected by pCMV-IGF-I1A-R/A or pCMV-IGF-I1A-R/K produced only proIGF-IA. Taken together, these results indicate that IGF-I propeptide A (proIGF-IA) has a biological activity that is similar in type and magnitude to that of mature IGF-I in stimulating chondrocytes.
Discussion
These data demonstrate that, when human IGF-I is overexpressed in bovine articular chondrocytes, promote IGF-I production, whereas the EB peptide inhibits IGF-I production. The finding that IGF-I1A-noEx6 was produced as efficiently as IGF-I1A, suggests that the N-terminal 16 amino acid sequence from Exon 4 is sufficient for efficient IGF-I production. Taken together, these results suggest that the different E peptides and parts of the E peptides exert distinct effects on IGF-I production.
Many polypeptide hormones and growth factors are initially synthesized as larger, inactive protein precursors, usually in the form of pre-pro-proteins, from which the biologically active mature molecules have to be liberated by proteolysis. IGF-I is also initially synthesized in the form of pre-pro-proteins.
However, the finding that proIGF-IA mutants that are resistant to EA peptide cleavage possessed biological activity indicates that the biological effects of the mutants are due to the propeptide rather than ACCEPTED MANUSCRIPT
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17 to mature IGF-I. These data suggest that the E peptide in proIGF-I does not prevent IGF-I binding to its receptor and subsequent internalization. A prior report similarly suggests that pro-IGF-IC (also termed full length mechano-growth factor), which includes an EC peptide, stimulated HEK 293 cells by binding to the IGF-I receptor [26] .
Mouse IGF-I has served as a model for the investigation of IGF-I processing. Human proIGF-IA and proIGF-IC are the corresponding pro forms to mouse proIGF-IA and proIGF-IB respectively [27] . We found that human proIGF-IA bound strongly to heparin, but proIGF-IC possessed minimal heparin binding activity. In a previous study [16] mouse proIGF-IA also bound to heparin, but unlike human IGF-IC, mouse proIGF-IB bound to heparin with greater affinity than mouse proIGF-IA. This species difference is consistent with the presence in mouse proIGF-IB of a putative heparin-binding segment (NKKTKL) in its EB peptide, and of a corresponding sequence in the EC peptide of human proIGF-IC of NKNTKS. The difference in sequence between NKKTKL and NKNTKS may explain the difference in heparin binding activity.
Although proIGF-IA is the corresponding isoform in both humans and rats, rat proIGF-IA has an Nglycosylation site at Asn100 in addition to the Asn92 that is present in human proIGF-IA. This second Nglycosylation site at Asn100 also exists in mouse proIGF-IA [28] . Both rat Asn92 and Asn100 have been reported to be glycosylated [29] . The present data show that the N-glycosylation at the Asn92 is sufficient for human proIGF-IA binding to heparin. It is not known what function, if any, the N-glycosylation at Asn100 in rat EA peptide contributes to rat proIGF-A, or whether the glycosylation at the conserved Asn92 mediates binding of rat proIGF-IA to heparin. Since neither human proIGF-IC nor rat proIGF-IB have putative N-glycosylation sites, this glycosylation-based mechanism of interaction with heparin would not apply to these isoforms.
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Human proIGF-IB has no analogue in rats or mice. In the present studies, CM from pAAV-IGF-I1B or pAAV-IGF-I2B transfected chondrocytes contained no heparin binding activity. In addition, these chondrocytes produced less IGF-I than chondrocytes transfected with pAAV-IGF-I1A, pAAV-IGF-I2A, pAAV-IGF-I1C or pAAV-IGF-I2C. To rule out the possibility that the absence of heparin binding activity was due to the low IGF-I levels in the CM of pAAV-IGF-I1B or pAAV-IGF-I2B transfected chondrocytes, we delivered pAAV-IGF-I1B to HEK 293 cells that produce high levels of IGF-I. The cells produced 654 ng/ml of IGF-I, yet no heparin binding activity was detected.
The E-peptides that are cleaved from proIGF-I isoforms to produce mature IGF-I may themselves have biological activities that are independent of IGF-I. Several studies have shown that E-peptides themselves have biological activities that are independent of IGF-I. Human EB-peptide has been reported to increase human bronchial epithelial cell proliferation [30] , localize to nucleoli [31] , induce neuroblastoma cell differentiation, stimulate neurite growth, increase ERK1/2 phosphorylation [32] , and augment proliferation and migration in multiple human cell lines [33] . Human EC-peptide, (mechano-growth factor), has been reported to increase stem cell migration, proliferation and differentiation and promote tissue repair and regeneration [34] [35] [36] [37] .
Heparin is closely related to heparan sulfate, a component of heparan sulfate proteoglycans (HSPGs) that are found within cartilage matrix (eg perlecan) and also on the surface of the chondrocytes (eg syndecans) [38, 39] . Future studies will be required to determine whether such HSPGs bind N-glycosylated proIGF-IA and, if so, whether they help control IGF-I bioactivity in the tissue.
Growth factors have been widely investigated for use in tissue repair and regeneration. In vitro and in vivo studies have identified IGF-I as an attractive chondrogenic agent [6, 7, 10, 11] . However, the application of IGF-I to articular cartilage repair is currently limited by rapid elimination from the repair site [40] .
Some growth factors, including BMP-2, FGF-2 and TGF-β1, bind to heparin. Others, including IGF-I,
have been genetically modified through the addition of a heparin binding domain, to bind to heparin [41] .
This feature has been employed to create new therepeutic agents by providing a sustained delivery of such growth factors from heparin-bearing vehicles to improve their reparative actions [42] . The present data indicate that, in addition to serving as the source of mature IGF-I, IGF-I propeptide A possesses the ability to both stimulate articular chondrocyte reparative activity and to bind to heparin. These properties suggest that proIGF-IA may hold potential as a therapeutic agent for articular cartilage repair. 
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